MAGELLAN-1, part 2: Glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

Authors
Category Primary study
JournalGastroenterology
Year 2017
This article has no abstract
Epistemonikos ID: c51e3cc7d582fe6e03e51ce78efcd8a67440fe29
First added on: Feb 08, 2025